Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer

Anticancer Research

Volumn 22, Issue 3, 2002, Pages 1919-1924

  Friedrich, Michael ^a   Villena Heinsen, Carlos ^a   Tilgen, Wolfgang ^a   Schmidt, Werner ^a   Reichrath, Jörg ^a   Axt Fliedner, Roland ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Breast cancer; Prognosis; Vitamin D receptor

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RISK; CANCER STAGING; CELL CYCLE S PHASE; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

EID: 0036329542     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Prognostic and predictive factors
2. Vitamin D receptor and cytokeratin expression may be progression indicators in human colon cancer
3. 1,25-Dihydroxyvitamin D receptor in breast cancer cells
4. 3 in human cancer cells
5. 3 receptor in breast cancer and relationship to prognosis
6. Possible role for vitamin D in controlling breast cancer cell proliferation
7. 1,25-Dihydroxyvitamin D3 suppresses cell growth, DNA, synthesis, and phosphorylation of retinoblastoma protein in a breast cancer cell line
8. Development of hybridomas secreting monoclonal antibodies to the chicken intestinal 1α-25-dihydroxyvitamin D3-receptor
9. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67
10. Comparative histological, histochemical, immunohistochemical and biochemical studies on estrogen receptors, lectin receptors, and Barr bodies in human breast cancer
11. Tamoxifen and chemotherapy for lymph node-negative estrogen receptor-positive breast cancer
12. Tamoxifen for early breast cancer: An overview of randomised trials
13. Polychemotherapy for early breast cancer: An overview of randomised trials
14. Nodal-negative Mammakarzinome - Was ist Standard, was ist experimentell?
15. Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer their relationship to biochemical and clinical indices
16. Immunocytochemical determination of estrogen receptor, progesterone receptor and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis
17. 3 receptor in primary breast cancer
18. 3-receptor turnover by dense amino acid labelling: Changes during receptor upregulation by vitamin D metabolites
19. Molecular biology of the vitamin D hormone
20. Association of breast cancer progression with a vitamin D receptor polymorphism
21. Association of a vitamin D receptor polymorphism with sporadic breast cancer development
22. 3-1α-hydroxylase in breast tissue
23. 3-1α-hydroxylase activity and regulation of side chain metabolism